Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Impact of Dutasteride on PSA Kinetics and Time to Progression in Men with PSA-only Recurrent Prostate Cancer

Charles E Myers, Michelle S McCarthy
doi: https://doi.org/10.1101/2021.05.03.21256519
Charles E Myers
Foundation for Cancer Research and Education, Earlysville, Virginia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: snuffymyers@me.com
Michelle S McCarthy
Foundation for Cancer Research and Education, Earlysville, Virginia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background AVODART After Radical Therapy For Prostate Cancer Study (ARTS) reported dutasteride reduced PSA doubling (PSADT) at two years by 66% and disease progression by 59%. The durability of the cancer control is unknown.

Objective Explore the impact of dutasteride on PSADT and time to progression in men with PSA-only recurrent disease.

Design, Setting and Participants Retrospective examination of the impact of dutasteride on PSA kinetics and time to progression with PSA-only recurrent prostate cancer.

Intervention Dutasteride daily.

Outcome, Measurement and Statistical Analysis Change in PSA over time was determined by linear regression of natural log of PSA versus time. The slope of that curve was used as a measure of exponential PSA progression. Impact of dutasteride on slope was analyzed using Wilcoxon signed-rank two-sided test. Time to progression was analyzed using Kaplan-Meier, univariant and multivariant Cox regression.

Results and Limitation Compared to men with BPH, patients showed little change in PSA during the first 3 months. Thereafter, the PSA resumed an exponential increase. PSADT was 10.3 months pre dutasteride and 24.8 months post dutasteride. Multivariant analysis showed a strong correlation between post dutasteride PSA kinetics and time to progression, with close to 50% relapse free at 10 years. Post-dutasteride, patients with PSADT >9 months had significantly better survival.

Conclusions Dutasteride slows PSADT in PSA-only recurrent prostate cancer. This decline correlated with time to disease progression with close to 50% progression free at 10 years.

Patient Summary Men with PSA-only recurrent prostate cancer on dutasteride experience a significant drop in the rate at which the PSA increases. If the PSA does not double between months 3-12, they are likely to remain free of metastases for many years.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by Foundation for Cancer Research and Education, Holewinski Family Foundation Inc and Schellhammer Urological Research Foundation.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Integreview IRB, 3815 S. Capital of Texas Highway, Suite 320, Austin TX 78704, 512-326-3007 | Fax: 512-593-6040 www.integreview.com, reviewed our protocol and designated that study was exempt under category 4.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵# Michelle.fcre{at}gmail.com

  • FUNDING This study was funded by Foundation for Cancer Research and Education, Holewinski Family Foundation Inc and Schellhammer Urological Research Foundation.

Data Availability

Study data is available upon request

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 05, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Impact of Dutasteride on PSA Kinetics and Time to Progression in Men with PSA-only Recurrent Prostate Cancer
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Impact of Dutasteride on PSA Kinetics and Time to Progression in Men with PSA-only Recurrent Prostate Cancer
Charles E Myers, Michelle S McCarthy
medRxiv 2021.05.03.21256519; doi: https://doi.org/10.1101/2021.05.03.21256519
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Impact of Dutasteride on PSA Kinetics and Time to Progression in Men with PSA-only Recurrent Prostate Cancer
Charles E Myers, Michelle S McCarthy
medRxiv 2021.05.03.21256519; doi: https://doi.org/10.1101/2021.05.03.21256519

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1103)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (504)
  • Epidemiology (9787)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2323)
  • Geriatric Medicine (223)
  • Health Economics (463)
  • Health Informatics (1566)
  • Health Policy (737)
  • Health Systems and Quality Improvement (606)
  • Hematology (238)
  • HIV/AIDS (507)
  • Infectious Diseases (except HIV/AIDS) (11658)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (240)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2149)
  • Nursing (134)
  • Nutrition (339)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1184)
  • Ophthalmology (366)
  • Orthopedics (129)
  • Otolaryngology (220)
  • Pain Medicine (148)
  • Palliative Medicine (50)
  • Pathology (313)
  • Pediatrics (698)
  • Pharmacology and Therapeutics (302)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2192)
  • Public and Global Health (4676)
  • Radiology and Imaging (781)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (211)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)